|
|  |
| The
Skinny on Fatty Acids: The Efficacy of Omega-3s
Please
read through the following information and click continue.
ACPE
Universal Program Number: 207-999-05-098-H01
Release Date: October 16, 2005
Expiration Date: October 16, 2008
Description
Epidemiologic
and interventional studies have found hypertriglyceridemia
to be a risk factor for coronary disease, particularly
in patients who have low HDL cholesterol (HDL-c) levels
and/or elevated LDL cholesterol (LDL-c) levels. While
this dyslipidemia may occur in the absence of other
disorders, it is frequently seen in patients who have
metabolic syndrome, diabetes, or obesity. Evidence
from epidemiologic and clinical secondary prevention
trials suggest that the omega-3 polyunsaturated fatty
acids (n-3 PUFAs), particularly eicosapentaenoic acid,
EPA, and docosahexaenoic acid, DHA, may play a significant
role in the prevention of coronary heart disease,
possibly by influencing serum lipids.
The purpose
of this program is to convey this evidence as well
as provide information regarding available types and
sources of omega-3 fatty acids. These include over
the counter plant-and fish oil-based supplements and
a newly approved prescription product. It is important
that pharmacists are aware of the appropriate treatment
options when advising patients with hypertriglyceridemia
or those otherwise at risk for coronary heart disease.
Learning
Objectives
Upon successful completion of this activity, the pharmacist should be better able
to:
- Review the current NCEP guidelines.
- Review the impact of various lipid medications on
lipoprotein metabolism.
- Discuss therapeutic approaches for hypertriglyceridemia treatment.
- Describe the role of omega-3 fatty acids in reducing the risk for
cardiovascular disease.
Target
Audience
Pharmacists
CE
Credit
A score of 70 percent is required to successfully complete
the CE quiz. You will have two opportunities to achieve a passing score.
The
Statement of Credit should be printed upon receipt; a duplicate copy
will be available in the participant's online transcript for further
viewing. Individuals must complete this program by October 16, 2008
to receive credit.
 NCPA
is approved by the Accreditation Council for Pharmacy Education as a
provider of continuing pharmacy education. This program will provide
1.5 contact hour(s) (0.15 CEUs) of continuing pharmacy education credit
under the number 207-999-05-098-H01.
Faculty
Information
Jennifer Cerulli, Pharm.D., BCPS, Associate
Professor of Pharmacy Practice, Albany College of Pharmacy, Albany,
New York.
William S. Harris, Ph.D., FAHA, Professor of Medicine,
University of Missouri-Kansas City, and Co-Director Lipid & Diabetes
Research Center, Kansas City, Missouri.
Faculty
Disclosure Statements
NCPA has a conflict of interest policy that requires course
faculty to disclose any real or apparent commercial financial affiliations
related to the content of their presentations/materials.
Commercial
Support Statement
This program is supported by an educational
grant from Reliant Pharmaceuticals. |
 |
Software
Requirements
PC
Windows 98 SE or above
Internet Explorer 5.5 or above
Netscape 7.02 or above
800 x 600 Minimum Monitor Resolution
Flash Player Plugin 6.0 or above
*Adobe Acrobat Reader |
MAC
Mac OS 10.2
Netscape 5.5 or above
800
x 600 Minimum Monitor Resolution
Flash Player Plugin 6.0 or above
*Adobe Acrobat Reader |
| *REQUIRED
TO VIEW PRINTABLE VERSION OF CE LESSON |
|
|
